AcquisitionsSep 8, 2026, 05:09 PM
Jin Medical Acquires Ginseng Assets for $159.4M via Share Issuance
AI Summary
Jin Medical International Ltd. announced its entry into a VIE Control Master Acquisition Agreement for US$159,415,729 to acquire ginseng-related biological and resource assets. The transaction, which aims to expand the company's core business into a broader senior-health platform, will be settled through the issuance of 71,282,488 Class A ordinary shares. The company also entered into a Financial Advisory Engagement Agreement, with the advisory fee payable in Class A ordinary shares.
Key Highlights
- Jin Medical International Ltd. entered into a VIE Control Master Acquisition Agreement for US$159,415,729.
- The acquisition includes ginseng-related biological and resource assets, focusing on future commercialization.
- Consideration includes the issuance of 71,282,488 Class A ordinary shares.
- Ancillary agreements include investment asset, equity, and debt transfers.
- The company entered into a Financial Advisory Engagement Agreement with Veltrion Haskel Holdings Limited.
- The advisory fee is 10.0% of the transaction value, payable in Class A ordinary shares valued at US$1.88 per share.
Price Impact
More from ZJYL